ENTPD1 and myeloid sarcoma: However, a conflicting study found that IFN-beta treatment, commonly utilized as a treatment for MS patients, can actually increase the expression of CD73 and levels of adenosine [88]; thus, further investigations are required to definitively illuminate the role of CD39/CD73 in MS development and progression.